Literature DB >> 15301592

Epidemiological characteristics of leprosy reactions: 15 years experience from north India.

Bhushan Kumar1, Sunil Dogra, Inderjeet Kaur.   

Abstract

A retrospective analysis of patient's leprosy clinic records at PGIMER, Chandigarh, India for the period 1983 to 1998 was undertaken to study the frequency, time of onset, and risk factors for leprosy reactions. Of the 2600 cases analyzed, 1494 were multibacillary and 1106 had paucibacillary disease. Presentation with reaction was common with 30.9% of our patients having reactions at the time of first visit. The incidence of reversal reaction (RR) was highest during 6 to 12 months after starting multi-drug therapy (MDT), thereafter declining gradually. Late RR occurred in 9.5% of all cases and was noted up to 7 years after treatment. Female gender, widespread disease, and multibacillary disease were identified as risk factors for RR. Erythema nodosum leprosum (ENL) reactions were noted to occur mostly during second or third year after starting MDT. Of the total number of patients who experienced ENL, 64.3% had recurrent episodes which continued for up to 8 years after the start of treatment. Lepromatous leprosy, female gender, and high Bacterial Index (>/=3) were recognized as risk factors for developing ENL. Occurrence of recurrent and late reactions, even though of mild severity, highlights the importance of recognizing and treating them promptly to prevent or reduce morbidity, complications, and further deterioration in the disability status. Although it is hoped that leprosy will have been eliminated at all levels by 2005, the recognition and management of these reactions will continue to be the most essential/significant task in the post elimination era.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301592     DOI: 10.1489/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  40 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

2.  Leprosy-related joint involvement.

Authors:  H L A Pereira; S L E Ribeiro; S N Pennini; E I Sato
Journal:  Clin Rheumatol       Date:  2008-09-19       Impact factor: 2.980

Review 3.  Leprosy in the 21st century.

Authors:  Cassandra White; Carlos Franco-Paredes
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

4.  Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil.

Authors:  Rodrigo Scaliante Moura; Gerson Oliveira Penna; Ludimila Paula Vaz Cardoso; Maria Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Mariane Martins de Araújo Stefani; Samira Bührer-Sékula
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

5.  Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy.

Authors:  Alexia Cusini; Huldrych F Günthard; Rainer Weber; Milo Huber; Jivko Kamarashev; Barbara Bertisch; Silke Peter; Bernhard Beck
Journal:  BMJ Case Rep       Date:  2009-12-01

6.  Risk factors for leprosy reactions in three endemic countries.

Authors:  David M Scollard; Celina M T Martelli; Mariane M A Stefani; Maria de Fatima Maroja; Laarni Villahermosa; Fe Pardillo; Krishna B Tamang
Journal:  Am J Trop Med Hyg       Date:  2014-12-01       Impact factor: 2.345

7.  Iris atrophy in patients with newly diagnosed multibacillary leprosy: at diagnosis, during and after completion of multidrug treatment.

Authors:  Ebenezer Daniel; P S S Sundar Rao; Timothy J Ffytche; Shirley Chacko; Hannah Ranjee Prasanth; Paul Courtright
Journal:  Br J Ophthalmol       Date:  2006-11-15       Impact factor: 4.638

8.  Lupus and leprosy: beyond the coincidence.

Authors:  F M Ribeiro; V E Gomez; E M N Albuquerque; E M Klumb; Y Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 9.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 10.  Neutrophil NETworking in ENL: Potential as a Putative Biomarker: Future Insights.

Authors:  Smrity Sahu; Keshav Sharma; Maryada Sharma; Tarun Narang; Sunil Dogra; Ranjana Walker Minz; Seema Chhabra
Journal:  Front Med (Lausanne)       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.